CH Peptides
Every formulation is curated with lab-grade ingredients, and we're syncing up the freshest data from our inventory so you see accurate availability as soon as the app loads.
Loading live inventory
Syncing 24 research sprays
Verifying lab supplies
Supabase + Stripe ready
Orders placed before 2 P.M. PST Monday through Friday are shipped out same day!
Looks like you haven't added any products to your cart yet.
Loading...
AOD-9604, known scientifically as Tyr-hGH Frag 177-191, is a synthetic peptide derived from the C-terminal fragment of human growth hormone (hGH). Other research identifiers include Tyr-Gly-Gly-Phe-Met-Ser-Ala-Ile-His-Thr. It was developed by Professor Frank Ng with Metabolic Pharmaceuticals Ltd as part of a series of peptide fragments designed to dissociate the lipolytic and anabolic effects of hGH.
This peptide consists of 15 amino acids: H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Thr-Ser-Leu-Glu-Gly-Ser-Cys-Gly-OH. It features a disulfide bridge between Cys182 and Cys189, crucial for its biological activity, preserving the lipolytic capacity without eliciting typical growth hormone responses.
AOD-9604 primarily interacts with the β3-adrenergic receptor and is believed to function as a partial agonist, activating lipolytic pathways, specifically the cAMP/PKA signaling cascade. This activation facilitates the breakdown of fat without altering insulin sensitivity. Though specific EC50 values are not extensively published, studies highlight its comparative specificity to induce lipolysis over anabolic effects inherent to full-length hGH.
AOD-9604 is soluble in sterile water, typically at concentrations of 1mg/mL. Reconstitution is recommended using sterile solvent, following lyophilization. The lyophilized form is stable at room temperature if kept dry and sealed, but once reconstituted, it remains stable for up to 2 weeks if stored at 2-8°C.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
AOD-9604, known scientifically as Tyr-hGH Frag 177-191, is a synthetic peptide derived from the C-terminal fragment of human growth hormone (hGH). Other research identifiers include Tyr-Gly-Gly-Phe-Met-Ser-Ala-Ile-His-Thr. It was developed by Professor Frank Ng with Metabolic Pharmaceuticals Ltd as part of a series of peptide fragments designed to dissociate the lipolytic and anabolic effects of hGH.
This peptide consists of 15 amino acids: H-Tyr-Leu-Arg-Ile-Val-Gln-Cys-Thr-Ser-Leu-Glu-Gly-Ser-Cys-Gly-OH. It features a disulfide bridge between Cys182 and Cys189, crucial for its biological activity, preserving the lipolytic capacity without eliciting typical growth hormone responses.
AOD-9604 primarily interacts with the β3-adrenergic receptor and is believed to function as a partial agonist, activating lipolytic pathways, specifically the cAMP/PKA signaling cascade. This activation facilitates the breakdown of fat without altering insulin sensitivity. Though specific EC50 values are not extensively published, studies highlight its comparative specificity to induce lipolysis over anabolic effects inherent to full-length hGH.
AOD-9604 is soluble in sterile water, typically at concentrations of 1mg/mL. Reconstitution is recommended using sterile solvent, following lyophilization. The lyophilized form is stable at room temperature if kept dry and sealed, but once reconstituted, it remains stable for up to 2 weeks if stored at 2-8°C.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
Chorionic Gonadotropin; commonly abbreviated as HCG. It is a glycoprotein hormone composed of alpha and beta subunits, predominantly characterized in human pregnancy. No specific research codes or development codes are associated with the basic glycoprotein.
HCG is a heterodimeric protein composed of two non-covalently linked subunits: the alpha subunit (92 amino acids) shared with other hormones like LH, FSH, and TSH, and the beta subunit (145 amino acids) which is unique to HCG. The beta subunit contains distinct segments: H-Trp-Met-Ser-Glu-His-Ile-Thr-Arg-Tyr-Leu-... and features specific disulfide bridges essential for activity and stability.
HCG acts as an agonist to the luteinizing hormone/chorionic gonadotropin receptor (LHCG receptor). Binding of HCG to its receptor activates pathways such as the cAMP/PKA signaling cascade, promoting steroidogenesis. EC50 values are variable based on assay and cellular system but are indicative of potent agonist activity.
HCG is soluble in sterile water at concentrations of 1mg/mL for research applications. Upon reconstitution, the solution must be stored at 2-8°C and is stable for up to 24 hours. Lyophilized HCG remains stable at -20°C until reconstitution.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
Retatrutide is referred to by its research code LY3502970. As of current knowledge, alternative naming conventions in the literature have not been extensively established.
Retatrutide is a peptide compound consisting of 39 amino acids. The exact amino acid sequence is: H-Thr-Lys-Asp-Glu-Leu-Gln-Ala-Ile-Arg-Trp-Leu-Lys-His-Glu-Arg-Asp-His-Gly-Ile-Lys-Lys-Glu-Cys-Leu-Glu-Glu-Val-Leu-Asp-Ser-Leu-Ala-Arg-Ala-Glu-Glu-Arg-OH. Specific modifications include N-terminal acetylation and C-terminal amidation to enhance its activity and stability. It is structurally designed to interact with multiple peptide receptors.
Retatrutide acts as an agonist at multiple receptors, including the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR), exhibiting multifaceted activity. Its mechanism enhances several intracellular signaling pathways, notably the cAMP/PKA and PI3K/Akt cascades. It demonstrates a unique binding profile, combining activities that influence metabolic pathways associated with glucose and lipid handling.
Retatrutide is notably soluble in sterile water at a concentration of 1mg/mL. For research applications, it is recommended to reconstitute the lyophilized form in an appropriate buffer and store it at -20°C to maintain stability. Once reconstituted, it remains stable for up to 3 weeks if stored under proper conditions.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.
Retatrutide is referred to by its research code LY3502970. As of current knowledge, alternative naming conventions in the literature have not been extensively established.
Retatrutide is a peptide compound consisting of 39 amino acids. The exact amino acid sequence is: H-Thr-Lys-Asp-Glu-Leu-Gln-Ala-Ile-Arg-Trp-Leu-Lys-His-Glu-Arg-Asp-His-Gly-Ile-Lys-Lys-Glu-Cys-Leu-Glu-Glu-Val-Leu-Asp-Ser-Leu-Ala-Arg-Ala-Glu-Glu-Arg-OH. Specific modifications include N-terminal acetylation and C-terminal amidation to enhance its activity and stability. It is structurally designed to interact with multiple peptide receptors.
Retatrutide acts as an agonist at multiple receptors, including the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR), exhibiting multifaceted activity. Its mechanism enhances several intracellular signaling pathways, notably the cAMP/PKA and PI3K/Akt cascades. It demonstrates a unique binding profile, combining activities that influence metabolic pathways associated with glucose and lipid handling.
Retatrutide is notably soluble in sterile water at a concentration of 1mg/mL. For research applications, it is recommended to reconstitute the lyophilized form in an appropriate buffer and store it at -20°C to maintain stability. Once reconstituted, it remains stable for up to 3 weeks if stored under proper conditions.
For laboratory research use only. Not for human or veterinary use. Not intended for diagnostic, therapeutic, or preventive applications.